Innate Pharma announces its financial calendar for 2019
Upcoming investor conferences
Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
Innate Pharma announces publication of monalizumab research in the prestigious “Cell” journal widening the horizon of immune checkpoint inhibitors
Innate Pharma appoints experts to new Strategic Advisory Board
Third quarter 2018 report
SITC 2018: further analyses of the Phase II study of the combination of monalizumab and cetuximab in head and neck patients show encouraging survival data in both subgroups of IO-naïve and IO-pretreated SCCHN patients
Number of shares and voting rights of Innate Pharma as at November 1, 2018
Clinical data featured as oral presentations at two major upcoming oncology conferences
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
